<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790577</url>
  </required_header>
  <id_info>
    <org_study_id>PakEmiratesMH2</org_study_id>
    <nct_id>NCT05790577</nct_id>
  </id_info>
  <brief_title>Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma</brief_title>
  <official_title>Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ishtiaq Ahmed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pak Emirates Military Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment&#xD;
      of Melasma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comparative study to evaluate Efficacy and tolerability of new lotion in the treatment of&#xD;
      Melasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2022</start_date>
  <completion_date type="Actual">February 15, 2023</completion_date>
  <primary_completion_date type="Actual">February 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy with measurement of MASI score 4 weeks apart</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Metformin 30% and 2% Nicotinamispde</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 30% plus Nicotinamide 2% in the reatment of Melasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kligman formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kligman formula in the treatment of Melasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Nicotinamide vs Kligman Formula</intervention_name>
    <description>Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma</description>
    <arm_group_label>Kligman formula</arm_group_label>
    <arm_group_label>Metformin 30% and 2% Nicotinamispde</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-50&#xD;
&#xD;
          -  No systemic therapy&#xD;
&#xD;
          -  All Co-morbids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age &gt;50&#xD;
&#xD;
          -  Taking oral treatment for melasma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ishtiaq Ahmed, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Pak Emirates Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PakEmiratesMH</name>
      <address>
        <city>Rawalpindi</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>August 6, 2022</study_first_submitted>
  <study_first_submitted_qc>March 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 16, 2023</last_update_submitted>
  <last_update_submitted_qc>March 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pak Emirates Military Hospital</investigator_affiliation>
    <investigator_full_name>Ishtiaq Ahmed</investigator_full_name>
    <investigator_title>Ishtiaq Ahmed</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

